LFF 269Alternative Names: LFF269
Latest Information Update: 04 Feb 2016
At a glance
- Originator Novartis
- Class Antihypertensives
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Essential hypertension
Most Recent Events
- 31 Aug 2013 Novartis initiates enrolment in a phase II trial for Essential hypertension in USA (NCT02047656)
- 10 May 2012 Novartis terminates a phase II trial in Essential hypertension in USA (NCT01373086)